8/27/2010

An FDA advisory panel is scheduled Sept. 20 to review Pradaxa, a blood thinner by Boehringer Ingelheim. The company is seeking to market the drug to prevent stroke in patients with atrial fibrillation. Pradaxa is approved overseas for preventing blood clots after hip- or knee-replacement surgery.

Related Summaries